213 related articles for article (PubMed ID: 34240279)
1. The first report of a JAK2 V617F-positive myeloproliferative neoplasm with initial manifestation as a rare pampiniform venous plexus thrombosis and review of the literature.
Jacobs J; Sharma D; Vnencak-Jones C
J Thromb Thrombolysis; 2022 Jan; 53(1):213-217. PubMed ID: 34240279
[TBL] [Abstract][Full Text] [Related]
2. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders.
De Stefano V; Fiorini A; Rossi E; Za T; Farina G; Chiusolo P; Sica S; Leone G
J Thromb Haemost; 2007 Apr; 5(4):708-14. PubMed ID: 17263783
[TBL] [Abstract][Full Text] [Related]
3. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
4. The JAK2 V617F mutation in patients with cerebral venous thrombosis.
Passamonti SM; Biguzzi E; Cazzola M; Franchi F; Gianniello F; Bucciarelli P; Pietra D; Mannucci PM; Martinelli I
J Thromb Haemost; 2012 Jun; 10(6):998-1003. PubMed ID: 22469236
[TBL] [Abstract][Full Text] [Related]
5. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
6. [Analysis of risk factors for thromboembolism in patients with JAK2
Zhang YH; Teng GS; Ma JY; Hu X; Du CX; Wang Y; Hu NB; Li YQ; Shao ZH; Bai J
Zhonghua Yi Xue Za Zhi; 2023 Dec; 103(45):3652-3657. PubMed ID: 38018064
[No Abstract] [Full Text] [Related]
7. The JAK2 V617F mutation and thrombosis.
Austin SK; Lambert JR
Br J Haematol; 2008 Nov; 143(3):307-20. PubMed ID: 19004076
[TBL] [Abstract][Full Text] [Related]
8. Dural Venous Sinus Thrombosis and Papilledema Related to
Donaldson L; Dhoot AS; Margolin E
Can J Neurol Sci; 2023 Mar; 50(2):194-200. PubMed ID: 34906267
[TBL] [Abstract][Full Text] [Related]
9. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis.
Colaizzo D; Amitrano L; Tiscia GL; Scenna G; Grandone E; Guardascione MA; Brancaccio V; Margaglione M
J Thromb Haemost; 2007 Jan; 5(1):55-61. PubMed ID: 17059429
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis.
Karaköse S; Oruç N; Zengin M; Akarca US; Ersöz G
Turk J Gastroenterol; 2015 Jan; 26(1):42-8. PubMed ID: 25698270
[TBL] [Abstract][Full Text] [Related]
11. JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms.
Payzin KB; Savasoglu K; Alacacioglu I; Ozdemirkiran F; Mutlu BB; Bener S; Calli AO; Kucukzeybek BB; Aksun S
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):525-33. PubMed ID: 24811089
[TBL] [Abstract][Full Text] [Related]
12. Splanchnic venous thrombosis driven by a constitutively activated JAK2 V617F philadelphia-negative myeloproliferative neoplasm: a case report.
Waiswa M; Seremba E; Ocama P; Ddungu H; Opio K; Okello C; O'shea T; Verhovsek M; Mutyabule R
Afr Health Sci; 2014 Dec; 14(4):1069-73. PubMed ID: 25834519
[TBL] [Abstract][Full Text] [Related]
13. JAK2 V617F mutation in patients with catastrophic intra-abdominal thromboses.
McMahon C; Abu-Elmagd K; Bontempo FA; Kant JA; Swerdlow SH
Am J Clin Pathol; 2007 May; 127(5):736-43. PubMed ID: 17439832
[TBL] [Abstract][Full Text] [Related]
14. The association of the JAK2 46/1 haplotype with non-splanchnic venous thrombosis.
Zerjavic K; Zagradisnik B; Lokar L; Krasevac MG; Vokac NK
Thromb Res; 2013 Aug; 132(2):e86-93. PubMed ID: 23845539
[TBL] [Abstract][Full Text] [Related]
15. [Thrombosis in myeloproliferative neoplasms].
Asakura H
Rinsho Ketsueki; 2018; 59(8):1034-1041. PubMed ID: 30185703
[TBL] [Abstract][Full Text] [Related]
16. Thrombosis among 1537 patients with JAK2
Zhang Y; Zhou Y; Wang Y; Teng G; Li D; Wang Y; Du C; Chen Y; Zhang H; Li Y; Fu L; Chen K; Bai J
Cancer Med; 2020 Mar; 9(6):2096-2105. PubMed ID: 31994332
[TBL] [Abstract][Full Text] [Related]
17. Influence of Blood Count, Cardiovascular Risks, Inherited Thrombophilia, and JAK2 V617F Burden Allele on Type of Thrombosis in Patients With Philadelphia Chromosome Negative Myeloproliferative Neoplasms.
Horvat I; Boban A; Zadro R; Antolic MR; Serventi-Seiwerth R; Roncevic P; Radman I; Sertic D; Vodanovic M; Pulanic D; Basic-Kinda S; Durakovic N; Zupancic-Salek S; Vrhovac R; Aurer I; Nemet D; Labar B
Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):53-63. PubMed ID: 30301673
[TBL] [Abstract][Full Text] [Related]
18. Should We Screen for Janus Kinase 2 V617F Mutation in Cerebral Venous Thrombosis?
Lamy M; Palazzo P; Agius P; Chomel JC; Ciron J; Berthomet A; Cantagrel P; Prigent J; Ingrand P; Puyade M; Neau JP
Cerebrovasc Dis; 2017; 44(3-4):97-104. PubMed ID: 28609766
[TBL] [Abstract][Full Text] [Related]
19. Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation.
Colaizzo D; Amitrano L; Guardascione MA; Tiscia GL; D'Andrea G; Longo VA; Grandone E; Margaglione M
Thromb Res; 2013 Aug; 132(2):e99-e104. PubMed ID: 23916380
[TBL] [Abstract][Full Text] [Related]
20. Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms.
Takata Y; Seki R; Kanajii T; Nohara M; Koteda S; Kawaguchi K; Nomura K; Nakamura T; Morishige S; Oku E; Osaki K; Hashiguchi E; Mouri F; Yoshimoto K; Nagafuji K; Okamura T
Kurume Med J; 2014; 60(3-4):89-97. PubMed ID: 24858412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
